Production of a novel influenza vaccine using insect cells: protection against drifted strains

A recombinant trivalent hemagglutinin (HA) vaccine produced in cell culture using the baculovirus expression system provides an attractive alternative to the current egg‐based influenza vaccine (Trivalent Inactivated Influenza Vaccine [TIV]) manufacturing process. The HA genes from the annual World...

Full description

Saved in:
Bibliographic Details
Published in:Influenza and other respiratory viruses 2007-01, Vol.1 (1), p.35-40
Main Authors: Cox, Manon M. J., Karl Anderson, D.
Format: Article
Language:English
Subjects:
Adjuvants
Animals
Antibiotics
Antigens
Baculoviridae - genetics
Baculovirus
Cell culture
Cell Line
Chemical bonds
Clinical Trials as Topic
Cloning
Cross Reactions
Deoxyribonucleic acid
Disease
DNA
Endotoxins
Genes
Genetic Vectors
Genomes
hemagglutinin
Hemagglutinin Glycoproteins, Influenza Virus - biosynthesis
Hemagglutinin Glycoproteins, Influenza Virus - genetics
Hemagglutinin Glycoproteins, Influenza Virus - immunology
Hemagglutinins
Humans
Immune response
Immune system
Immunogenicity
Influenza
Influenza Vaccines - biosynthesis
Influenza Vaccines - genetics
Influenza Vaccines - immunology
Insect cells
Insecta
Insects
Manufacturing
Manufacturing industry
Medical research
Morphology
Preservatives
Proteins
Respiratory diseases
Review
vaccine
Vaccines
Vaccines, Synthetic - biosynthesis
Vaccines, Synthetic - genetics
Vaccines, Synthetic - immunology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A recombinant trivalent hemagglutinin (HA) vaccine produced in cell culture using the baculovirus expression system provides an attractive alternative to the current egg‐based influenza vaccine (Trivalent Inactivated Influenza Vaccine [TIV]) manufacturing process. The HA genes from the annual World Health Organization‐recommended strains are cloned, expressed, and purified using a general purification process. Here, we provide an overview of the expression technology used to make the annual adjustment of the vaccine and the clinical studies completed to date with recombinant HA. The highly purified protein vaccine, administered at three times higher antigen content than TIV, results in stronger immunogenicity, a long‐lasting immune response and provides cross‐protection against drift variant influenza viruses. Furthermore, the vaccine does not contain egg proteins, adjuvants, preservatives, endotoxins, or antibiotics and can therefore be used in a broader population.
ISSN:1750-2640
1750-2659
DOI:10.1111/j.1750-2659.2006.00007.x